Total Payments
$7,096
2024 Payments
$353.66
Companies
18
Transactions
50
Medicare Patients
2,780
Medicare Billing
$341,776
Payment Breakdown by Category
Consulting$3,060 (43.1%)
Travel$1,793 (25.3%)
Food & Beverage$1,469 (20.7%)
Other$500.00 (7.0%)
Research$188.72 (2.7%)
Education$85.47 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $3,060 | 1 | 43.1% |
| Travel and Lodging | $1,793 | 6 | 25.3% |
| Food and Beverage | $1,469 | 33 | 20.7% |
| Honoraria | $500.00 | 1 | 7.0% |
| Unspecified | $188.72 | 3 | 2.7% |
| Education | $85.47 | 6 | 1.2% |
Payments by Type
General
$6,907
47 transactions
Research
$188.72
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $3,060 | 1 | $0 (2020) |
| Elekta, Inc. | $2,035 | 15 | $0 (2024) |
| AstraZeneca UK Limited | $1,264 | 9 | $0 (2019) |
| ABBVIE INC. | $188.72 | 3 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $171.73 | 9 | $0 (2022) |
| Genentech, Inc. | $104.00 | 1 | $0 (2019) |
| Genentech USA, Inc. | $77.03 | 1 | $0 (2024) |
| Gilead Sciences, Inc. | $34.18 | 1 | $0 (2023) |
| Incyte Corporation | $24.47 | 1 | $0 (2024) |
| Aveo Pharmaceuticals, Inc. | $20.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $353.66 | 7 | Elekta, Inc. ($100.58) |
| 2023 | $141.71 | 4 | AbbVie Inc. ($92.34) |
| 2022 | $14.13 | 1 | Janssen Pharmaceuticals, Inc ($14.13) |
| 2021 | $181.13 | 10 | Janssen Pharmaceuticals, Inc ($144.26) |
| 2020 | $3,060 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($3,060) |
| 2019 | $1,497 | 13 | AstraZeneca UK Limited ($1,264) |
| 2018 | $1,750 | 12 | Elekta, Inc. ($1,726) |
| 2017 | $97.59 | 2 | Elekta, Inc. ($97.59) |
All Payment Transactions
50 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $24.47 | General |
| Category: Hematology/Oncology | ||||||
| 09/08/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $77.03 | General |
| 08/14/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: Oncology | ||||||
| 06/07/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2024 | ABBVIE INC. | — | — | In-kind items and services | $96.38 | Research |
| Study: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | ||||||
| 02/21/2024 | Elekta, Inc. | MOSAIQ (Device) | Food and Beverage | In-kind items and services | $100.58 | General |
| Category: ONCOLOGY INFORMATICS SOLUTIONS | ||||||
| 07/14/2023 | Amgen Inc. | Vectibix (Biological) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: Oncology | ||||||
| 06/03/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $34.18 | General |
| 06/02/2023 | AbbVie Inc. | — | — | In-kind items and services | $65.87 | Research |
| Study: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | ||||||
| 06/02/2023 | AbbVie Inc. | — | — | In-kind items and services | $26.47 | Research |
| Study: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | ||||||
| 01/13/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 12/10/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/29/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/29/2021 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Education | In-kind items and services | $11.44 | General |
| Category: ONCOLOGY | ||||||
| 08/31/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $22.18 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/14/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/03/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 05/28/2021 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $13.93 | General |
| Category: ONCOLOGY | ||||||
| 04/29/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 03/25/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $30.47 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 03/18/2021 | Epizyme, Inc., | TAZVERIK (Drug) | Education | In-kind items and services | $11.50 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2020 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug) | Consulting Fee | Cash or cash equivalent | $3,060.00 | General |
| Category: Oncology | ||||||
| 10/24/2019 | Elekta, Inc. | Unity (Device), Icon, Mosaiq | Food and Beverage | Cash or cash equivalent | $99.29 | General |
| Category: ELEKTA LINEAR ACCELERATOR (MR) | ||||||
| 10/24/2019 | Elekta, Inc. | Unity (Device), Icon, Mosaiq | Food and Beverage | Cash or cash equivalent | $10.92 | General |
| Category: ELEKTA LINEAR ACCELERATOR (MR) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | ABBVIE INC. | $96.38 | 1 |
| Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | AbbVie Inc. | $92.34 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 748 | 1,196 | $161,862 | $95,414 |
| 2022 | 10 | 727 | 1,065 | $144,619 | $84,645 |
| 2021 | 9 | 723 | 1,117 | $161,511 | $100,554 |
| 2020 | 8 | 582 | 906 | $103,800 | $61,162 |
Total Patients
2,780
Total Services
4,284
Medicare Billing
$341,776
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 222 | 411 | $51,610 | $27,895 | 54.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 87 | 168 | $29,502 | $17,889 | 60.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 97 | 186 | $23,756 | $14,336 | 60.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 41 | 77 | $13,524 | $8,795 | 65.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 50 | 56 | $9,421 | $7,301 | 77.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 36 | 36 | $7,860 | $4,792 | 61.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 78 | 99 | $8,982 | $4,572 | 50.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 70 | 79 | $7,054 | $3,106 | 44.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 29 | 29 | $5,277 | $2,905 | 55.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 38 | $2,915 | $2,285 | 78.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 17 | $1,962 | $1,538 | 78.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 90 | 224 | $40,034 | $23,830 | 59.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 205 | 331 | $42,194 | $22,747 | 53.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 63 | 63 | $13,672 | $8,436 | 61.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 134 | 168 | $15,176 | $7,302 | 48.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 60 | 73 | $9,275 | $6,340 | 68.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 33 | 35 | $6,711 | $5,037 | 75.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 53 | 64 | $5,845 | $3,424 | 58.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 25 | $4,817 | $2,656 | 55.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 19 | $1,886 | $1,483 | 78.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 24 | $1,657 | $1,313 | 79.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $1,970 | $1,180 | 59.9% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 14 | 14 | $1,149 | $775.71 | 67.5% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2022 | 12 | 13 | $233.60 | $121.84 | 52.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 114 | 308 | $54,922 | $32,788 | 59.7% |
About Dr. Benjamin Solomon, MD
Dr. Benjamin Solomon, MD is a Hematology & Oncology healthcare provider based in Sioux Falls, South Dakota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1912107368.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Solomon, MD has received a total of $7,096 in payments from pharmaceutical and medical device companies, with $353.66 received in 2024. These payments were reported across 50 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($3,060).
As a Medicare-enrolled provider, Solomon has provided services to 2,780 Medicare beneficiaries, totaling 4,284 services with total Medicare billing of $341,776. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine, Student in an Organized Health Care Education/Training Program
- Location Sioux Falls, SD
- Active Since 07/24/2007
- Last Updated 10/16/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1912107368
Products in Payments
- Vitrakvi (Drug) $3,060
- IMFINZI (Drug) $1,264
- Esteya (Device) $1,263
- Mosaiq (Device) $522.95
- XARELTO (Drug) $171.73
- Unity (Device) $110.21
- Non-Covered Product (Drug) $104.00
- MOSAIQ (Device) $100.58
- Icon (Device) $37.91
- JAKAFI (Drug) $24.47
- FOTIVDA (Drug) $20.00
- ILARIS (Biological) $18.82
- KEYTRUDA (Biological) $18.09
- CALQUENCE (Drug) $17.11
- Vectibix (Biological) $15.19
- BELEODAQ (Drug) $13.93
- TAZVERIK (Drug) $11.50
- QINLOCK (Drug) $11.44
- Idhifa (Drug) $10.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Sioux Falls
Kelly Mccaul, M.d, M.D
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Dr. Brian Leyland-Jones, M.d, M.D
Hematology & Oncology — Payments: $596,161
Hematology & Oncology $596,161
Miroslaw Mazurczak, M.d, M.D
Hematology & Oncology — Payments: $2,793
Hematology & Oncology $2,793
Mark Huber, M.d, M.D
Hematology & Oncology — Payments: $1,305
Hematology & Oncology $1,305
Dr. Ryan Vaca, M.d, M.D
Hematology & Oncology — Payments: $1,173
Hematology & Oncology $1,173
Dr. Houman Nourkeyhani, M.d, M.D
Hematology & Oncology — Payments: $794.82
Hematology & Oncology $794.82